FIELD: biotechnology.
SUBSTANCE: invention relates to production of chimeric antigenic receptors, and can be used in anticancer therapy. Nucleic acid encoding a chimeric antigen receptor polypeptide targeted to CS1 is constructed. An expression vector is transduced by human T-cells to obtain a population of said cells expressing a chimeric antigen receptor aimed at CS1.
EFFECT: obtained cell population is effective in treating oncological disease, in which CS1 is expressed, for example, such as multiple myeloma.
11 cl, 12 dwg, 5 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| IMMUNOTHERAPY CELLS DESIGNED FOR TARGETING ANTIGEN PRESENT SIMULTANEOUSLY ON IMMUNE CELLS AND ON PATHOLOGICAL CELLS | 2015 |
|
RU2714258C2 |
| MUC16-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USE | 2019 |
|
RU2795198C2 |
| CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR CANCER TREATMENT | 2019 |
|
RU2811466C2 |
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
